ASCO 2023 | PSMA PET imaging in defining mPC and understanding long-term dynamics and treatment implications

Ravi Amrit Madan, MD, National Cancer Institute, Bethesda, MD, discusses the use of PSMA PET imaging technology to define metastatic prostate cancer. This imaging technology allows for the identification of microscopic disease, which may influence treatment decisions and potentially avoid unnecessary side effects of surgery or radiation. However, there is limited understanding of the long-term dynamics of PSMA PET findings in patients with recurrent prostate cancer. The current treatment approaches for these patients are based on trial results from conventional imaging techniques, such as CT scans or bone scans, which may not accurately reflect the population identified through PSMA PET. Dr Madan highlights the need for further research and data to guide the management of these patients and avoid escalating toxicity in those with clinically insignificant disease. The National Cancer Institute plans to conduct a trial to monitor patients with positive PSMA PET findings and negative conventional imaging over time, aiming to better comprehend the natural history and evolution of this specific manifestation of prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.